Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH [benign prostatic hyperplasia]: an Open-Labeled Safety and Efficacy Assessment Study.

X
Trial Profile

Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH [benign prostatic hyperplasia]: an Open-Labeled Safety and Efficacy Assessment Study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Registrational
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 17 Aug 2009 Status changed from active, no longer recruiting to completed as reported in an AEterna Zentaris media release.
    • 15 Jun 2009 Data analysis has been brought foward from the scheduled fourth quarter into the third quarter of 2009, according to a AEterna Zentaris media release.
    • 14 May 2008 Status changed from recruiting to in progress, according to AEterna Zentaris media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top